These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38083484)

  • 1. Portable electrical impedance tomography (EIT) system stages non-alcoholic fatty liver disease for potential screening and monitoring at home.
    Li JHW; Touboul A; Zouari F; Cheung PT; Wei E; Wong EC; Zhou IY; Yuen MF; Seto WK; Mak LY; Chan RW
    Annu Int Conf IEEE Eng Med Biol Soc; 2023 Jul; 2023():1-4. PubMed ID: 38083484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unmixing multi-spectral electrical impedance tomography (EIT) predicts clinical-standard controlled attenuation parameter (CAP) for nonalcoholic fatty liver disease classification: a feasibility study.
    Touboul A; Zouari F; Minciullo L; Modak D; Lee RMV; Wong EC; Yuen MF; Seto WK; Mak LY; Chan RW
    Annu Int Conf IEEE Eng Med Biol Soc; 2022 Jul; 2022():576-579. PubMed ID: 36086553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electrical impedance tomography for non-invasive identification of fatty liver infiltrate in overweight individuals.
    Chang CC; Huang ZY; Shih SF; Luo Y; Ko A; Cui Q; Sumner J; Cavallero S; Das S; Gao W; Sinsheimer J; Bui A; Jacobs JP; Pajukanta P; Wu H; Tai YC; Li Z; Hsiai TK
    Sci Rep; 2021 Oct; 11(1):19859. PubMed ID: 34615918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic comparison of vibration-controlled transient elastography and MRI techniques in overweight and obese patients with NAFLD.
    Nogami A; Yoneda M; Iwaki M; Kobayashi T; Kessoku T; Honda Y; Ogawa Y; Imajo K; Higurashi T; Hosono K; Kirikoshi H; Saito S; Nakajima A
    Sci Rep; 2022 Dec; 12(1):21925. PubMed ID: 36535977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Performance of Transient Elastography With Comparison to Quantitative Magnetic Resonance Imaging, Ultrasound, and Biopsy in Children and Adolescents With Known or Suspected Fatty Liver Disease.
    P V Alves V; T Trout A; Dewit M; Mouzaki M; Arce-Clachar AC; S Bramlage K; R Dillman J; A Xanthakos S
    Child Obes; 2023 Oct; 19(7):461-469. PubMed ID: 36269577
    [No Abstract]   [Full Text] [Related]  

  • 6. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis.
    Selvaraj EA; Mózes FE; Jayaswal ANA; Zafarmand MH; Vali Y; Lee JA; Levick CK; Young LAJ; Palaniyappan N; Liu CH; Aithal GP; Romero-Gómez M; Brosnan MJ; Tuthill TA; Anstee QM; Neubauer S; Harrison SA; Bossuyt PM; Pavlides M;
    J Hepatol; 2021 Oct; 75(4):770-785. PubMed ID: 33991635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A meta-analysis on the diagnostic performance of magnetic resonance imaging and transient elastography in nonalcoholic fatty liver disease.
    Gu Q; Cen L; Lai J; Zhang Z; Pan J; Zhao F; Yu C; Li Y; Chen C; Chen W; Shen Z
    Eur J Clin Invest; 2021 Feb; 51(2):e13446. PubMed ID: 33128454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct Comparison of Quantitative US versus Controlled Attenuation Parameter for Liver Fat Assessment Using MRI Proton Density Fat Fraction as the Reference Standard in Patients Suspected of Having NAFLD.
    Jung J; Han A; Madamba E; Bettencourt R; Loomba RR; Boehringer AS; Andre MP; Erdman JW; O'Brien WD; Fowler KJ; Sirlin CB; Loomba R
    Radiology; 2022 Jul; 304(1):75-82. PubMed ID: 35348378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-Invasive Electrical Impedance Tomography for Multi-Scale Detection of Liver Fat Content.
    Luo Y; Abiri P; Zhang S; Chang CC; Kaboodrangi AH; Li R; Sahib AK; Bui A; Kumar R; Woo M; Li Z; Packard RRS; Tai YC; Hsiai TK
    Theranostics; 2018; 8(6):1636-1647. PubMed ID: 29556346
    [No Abstract]   [Full Text] [Related]  

  • 10. Usefulness of controlled attenuation parameter in monitoring clinically relevant decline of hepatic steatosis for non-alcoholic fatty liver disease.
    Wang JH; Ou HY; Yen YH; Hung CH; Lu SN
    Liver Int; 2023 Sep; 43(9):1901-1908. PubMed ID: 37249034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates.
    Garteiser P; Castera L; Coupaye M; Doblas S; Calabrese D; Dioguardi Burgio M; Ledoux S; Bedossa P; Esposito-Farèse M; Msika S; Van Beers BE; Jouët P
    JHEP Rep; 2021 Dec; 3(6):100381. PubMed ID: 34786549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography.
    Imajo K; Kessoku T; Honda Y; Tomeno W; Ogawa Y; Mawatari H; Fujita K; Yoneda M; Taguri M; Hyogo H; Sumida Y; Ono M; Eguchi Y; Inoue T; Yamanaka T; Wada K; Saito S; Nakajima A
    Gastroenterology; 2016 Mar; 150(3):626-637.e7. PubMed ID: 26677985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRI Assessment of Treatment Response in HIV-associated NAFLD: A Randomized Trial of a Stearoyl-Coenzyme-A-Desaturase-1 Inhibitor (ARRIVE Trial).
    Ajmera VH; Cachay E; Ramers C; Vodkin I; Bassirian S; Singh S; Mangla N; Bettencourt R; Aldous JL; Park D; Lee D; Blanchard J; Mamidipalli A; Boehringer A; Aslam S; Leinhard OD; Richards L; Sirlin C; Loomba R
    Hepatology; 2019 Nov; 70(5):1531-1545. PubMed ID: 31013363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial.
    Cui J; Philo L; Nguyen P; Hofflich H; Hernandez C; Bettencourt R; Richards L; Salotti J; Bhatt A; Hooker J; Haufe W; Hooker C; Brenner DA; Sirlin CB; Loomba R
    J Hepatol; 2016 Aug; 65(2):369-76. PubMed ID: 27151177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of the combined FibroMeter vibration-controlled transient elastography algorithm in Chinese patients with non-alcoholic fatty liver disease.
    Loong TC; Wei JL; Leung JC; Wong GL; Shu SS; Chim AM; Chan AW; Choi PC; Tse YK; Chan HL; Wong VW
    J Gastroenterol Hepatol; 2017 Jul; 32(7):1363-1369. PubMed ID: 27936280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis.
    Caussy C; Alquiraish MH; Nguyen P; Hernandez C; Cepin S; Fortney LE; Ajmera V; Bettencourt R; Collier S; Hooker J; Sy E; Rizo E; Richards L; Sirlin CB; Loomba R
    Hepatology; 2018 Apr; 67(4):1348-1359. PubMed ID: 29108123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective, Same-Day, Direct Comparison of Controlled Attenuation Parameter With the M vs the XL Probe in Patients With Nonalcoholic Fatty Liver Disease, Using Magnetic Resonance Imaging-Proton Density Fat Fraction as the Standard.
    Caussy C; Brissot J; Singh S; Bassirian S; Hernandez C; Bettencourt R; Rizo E; Richards L; Sirlin CB; Loomba R
    Clin Gastroenterol Hepatol; 2020 Jul; 18(8):1842-1850.e6. PubMed ID: 31843596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative multiparametric magnetic resonance imaging can aid non-alcoholic steatohepatitis diagnosis in a Japanese cohort.
    Imajo K; Tetlow L; Dennis A; Shumbayawonda E; Mouchti S; Kendall TJ; Fryer E; Yamanaka S; Honda Y; Kessoku T; Ogawa Y; Yoneda M; Saito S; Kelly C; Kelly MD; Banerjee R; Nakajima A
    World J Gastroenterol; 2021 Feb; 27(7):609-623. PubMed ID: 33642832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal Threshold of Controlled Attenuation Parameter for Detection of HIV-Associated NAFLD With Magnetic Resonance Imaging as the Reference Standard.
    Ajmera VH; Cachay ER; Ramers CB; Bassirian S; Singh S; Bettencourt R; Richards L; Hamilton G; Middleton M; Fowler K; Sirlin C; Loomba R
    Clin Infect Dis; 2021 Jun; 72(12):2124-2131. PubMed ID: 32975278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Magnetic resonance imaging and transient elastography in the management of Nonalcoholic Fatty Liver Disease (NAFLD).
    Han MA; Saouaf R; Ayoub W; Todo T; Mena E; Noureddin M
    Expert Rev Clin Pharmacol; 2017 Apr; 10(4):379-390. PubMed ID: 28277807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.